Lixisenatide Doesn't Affect Cardiovascular Risk in T2DM

Share this content:
Lixisenatide Doesn't Affect Cardiovascular Risk in T2DM
Lixisenatide Doesn't Affect Cardiovascular Risk in T2DM

THURSDAY, Dec. 3, 2015 (HealthDay News) -- The addition of lixisenatide to usual care does not impact the rate of major cardiovascular events or other serious adverse events among patients with type 2 diabetes and a recent acute coronary syndrome, according to a study published in the Dec. 3 issue of the New England Journal of Medicine.

Marc A. Pfeffer, M.D., Ph.D., from Brigham and Women's Hospital in Boston, and colleagues randomized patients with type 2 diabetes who had had myocardial infarction or who had been hospitalized for unstable angina within the prior 180 days to lixisenatide or placebo. A total of 6,068 patients were randomized and followed for a median of 25 months.

The researchers found that a primary end point event (cardiovascular death, myocardial infarction, stroke, or hospitalization for unstable angina) occurred in 13.4 and 13.2 percent of the lixisenatide and placebo groups, respectively (hazard ratio, 1.02; 95 percent confidence interval, 0.89 to 1.17), demonstrating noninferiority (P < 0.001) but not superiority (P = 0.81). No significant between-group differences were seen in the rate of hospitalization for heart failure (hazard ratio, 0.96; 95 percent confidence interval, 0.75 to 1.23) or death (hazard ratio, 0.94; 95 percent confidence interval, 0.78 to 1.13).

"The neutral cardiovascular profile associated with lixisenatide will inform physicians' and patients' decisions regarding the use of this agent as an adjunctive therapy to control the glycated hemoglobin level safely," the authors write.

The study was funded by Sanofi, the manufacturer of lixisenatide.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »